Heart Valve Repair and Replacement

Our doctors are currently seeing patients through in-person and video visits.

When you call to schedule an appointment with our doctors, please let the team know if you want an in-person or video visit. If you request a video visit, our team will walk you through the simple process of arranging one. Call your preferred campus today to schedule an in-person or video visit* appointment.
* This service is open to new and existing patients.

FDA approves TAVR for low-risk patients with severe symptomatic aortic stenosis

Do you qualify for TAVR?

Your heart has four valves that work hard every day to make sure your blood flows in the right direction. So when a valve becomes weakened due to age, a congenital disability, an infection, or another disease, you may not be feeling your best. If you recently learned you have a heart valve that needs repair or replacement, NewYork-Presbyterian offers you a world-class team of heart specialists who can put together a treatment plan that gets you back on the path to wellness. Their exceptional experience results in extraordinary outcomes in heart valve care.

Leaders in the Development of Valve Treatment

Our team includes doctors who have led significant studies evaluating a novel, less-invasive techniques for repairing and replacing damaged mitral valves, aortic valves, and pulmonary valves. Today our heart valve program is one of the largest of its kind in the country.

  • Aortic valve replacement. We have the most experience in the nation with transcatheter aortic valve replacement (TAVR), a minimally invasive treatment for aortic valve disease. Almost half of the interventional cardiologists who perform TAVR in this country were trained by our specialists.
  • Mitral valve repair. Our mitral valve centers offer patients treatment options not available just a few years ago. They continue to shift the surgical approach from replacement to repair and from open surgery to minimal access methods. With increasing evidence that mitral valve repair is better than replacement, the surgical treatment of mitral valve disease is becoming more of a specialty operation that is best performed at high-volume academic medical centers such as NewYork-Presbyterian.

A Team of Experts

We combine the expertise of cardiologists, interventional cardiologists, cardiothoracic surgeons, and cardiac imaging specialists to provide you with high-quality, personalized care.

Advancing the Field through Research

Virtually every advance in TAVR has had its roots at NewYork-Presbyterian. Our doctors were the principal investigators of the national clinical trials establishing the effectiveness of TAVR. In the PARTNER trial, our clinicians helped to establish that balloon-expandable transcatheter valve replacement in people at high risk for traditional surgery is safe and as effective as open-heart surgery regarding one-year survival. Most recently, our team led the charge in the PARTNER 3 trial, which demonstrated that patients with severe symptomatic aortic stenosis who are low risk for surgical intervention treated with TAVR had low rates of death or disabling stroke at one year, a shorter length of stay than following open-heart surgery, and a 96% discharge rate to home or self-care.

A Record of Success

Our specialists perform the largest volume of valve procedures in the northeastern United States. We've completed more than 4,600 TAVR procedures. Our TAVR program is now among the largest centers in the United States, with more than 550 cases a year and 70 percent of our patients are discharged by the second day. Every heart procedure carries with it some risk, but at NewYork-Presbyterian, our in-hospital mortality rates for valve surgery patients are significantly lower than expected and below national rates.

Clinical Trial Opportunities

Our investigators are participating in several national clinical trials evaluating new heart valve devices and approaches, including those for people needing aortic valve surgery and mitral valve surgery. We were principal investigators for the multicenter national PARTNER 3 trial assessing TAVR in patients with severe symptomatic aortic stenosis who are low risk for surgical intervention. You may have the opportunity to participate in a clinical trial of a new heart valve therapy.